R-ACTIVATED PROTEIN C (APC) DOSE RANGING STUDY IN HEREDITARY PROTEIN C DEFICIENCY

R 激活蛋白 C (APC) 治疗遗传性蛋白 C 缺乏症的剂量范围研究

• 批准号: 5222210
• 负责人: KENNETH BAUER
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5222210
• 关键词: blood /lymphatic pharmacology; blood coagulation disorders; clinical research; clinical trial phase I; congenital blood protein disorder; dosage; drug screening /evaluation; enzyme activity; fibrinolytic agents; human subject; pharmacokinetics; protein C

This study will determine the intravenous infusion rate of r-activated protein C and plasma concentration of APC that reduces markers of activated coagulation in patients with hereditary protein C deficiency. The study will determine the pharmacokinetics of rAPC in hereditary protein C deficient patients and determine the safety of 24-hour rAPC infusions.

这项研究将确定r-激活的静脉输注速度。 蛋白C和血浆APC浓度降低的标志物 遗传性蛋白C缺乏症患者的活化凝血功能。 这项研究将确定RAPC在遗传性中的药代动力学 蛋白C缺乏症患者24小时RAPC的安全性研究 输液。